Peptone, founded in 2018, specialises in the development of novel therapeutics against Intrinsically disordered proteins (IDP) for cancer and inflammatory diseases, to name a few. Peptone's approach stems from experimental biophysics, supercomputing, and machine learning.
Some insights
Peptone's investment in Bellinzona follows a 40 million dollar funding round completed in April 2022. The company plans to create up to 20 new jobs in their new Swiss hub by the end of 2023 and around 30 highly specialised qualified employees will be working in interdisciplinary teams in Bellinzona.